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Background: Sugar-sweetened beverage consumption in high quantities impairs lipid metabo-
lism and therefore causes metabolic disorders in obese subjects. However, the effect of sugar 
sweetened beverages in lower doses on normal weight healthy subjects remains less clear.  
Objective: The aim of the study was to investigate the impact of sugar-sweetened beverage 
consumption over 7 weeks on low density lipoprotein particle size and distribution.  
Design: 96 normal weight, healthy young male subjects were included in a randomized, double 
blind, monocentric, controlled nutritional trial and were randomly assigned to 4 intervention 
groups. Over a period of 7 weeks, subjects were instructed to consume on a daily basis 600ml 
of sugar-sweetened beverages containing either 80g fructose, 80g glucose or 80g sucrose, 
whereas a control group was advised to abstain completely from sugar-sweetened beverages. 
Results: Small low density lipoprotein particles (22-25.6nm diameter) increased and large low 
density lipoprotein particles (25.6-28.5nm diameter) decreased after sugar-sweetened beverage 
consumption compared with baseline (p = 0.04). The sucrose containing intervention decreased 
the largest low density lipoprotein particles (27.2-28.5nm diameter) significantly (p = 0.039). 
Conclusion: This study shows that even moderate consumption of sugar-sweetened beverag-
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Strong epidemiological evidence suggests a causal relation between fructose consumption and 
metabolic disorders (1, 2). Over the past decades, sugar-sweetened beverages (SSBs) turned 
into the leading source of added sugars in the United States (3). After the introduction of high-
fructose corn syrup as a beverage sweetener, there was simultaneously an increase in levels of 
overweight and obesity in all population groups observed (4). Additionally, caloric sweetener 
consumption has been associated with dyslipidaemia, known to increase the risk of cardiovas-
cular diseases (5, 6). In fact, regular consumption of SSBs is associated with an increased risk 
of coronary heart disease (7, 8). SSB consumption was also found to be associated with an 
elevated risk of developing type 2 diabetes (9).   
Moreover, animal studies showed, that fructose, in contrast to glucose, induces dyslipidaemia 
and insulin resistance (10, 11, 12, 13, 14). A more recent study in overweight humans showed 
fructose-sweetened, but not glucose-sweetened, beverages to increase visceral adiposity and 
lipids and also to decrease insulin sensitivity (15). In a cross-sectional study in schoolchildren 
an association between high fructose intake with decreased low density lipoprotein (LDL) parti-
cle size was found (2). Secondary, there is an association between smaller LDL particle size 
and the metabolic syndrome and may be an early marker for atherosclerosis and type 2 diabe-
tes (16, 17, 18).  
There are several important differences between the metabolism of fructose and glucose (4, 
19). First of all, fructose as a highly lipogenic substrate increases lipid synthesis in various ways 
(15). After consumption of fructose, it gets rapidly cleared from the blood plasma and metabo-
lized by the enzyme fructokinase in the liver (20, 21). Furthermore, the rate of fructose being 
absorbed from the portal blood circulation by the liver is higher than the rate of glucose being 
absorbed (19). While the enzymes phosphorylating glucose (phosphofructokinase and glucoki-
nase) are regulated by the energy status of the cell and insulin, fructokinase is not and bypass-
es major regulatory steps of glycolysis (20, 21). Consequently, it leads to an increased produc-
tion of triose phosphates, which then leads to increased de novo synthesis of Acyl coencyme A 
(acyl-CoA), triglycerides and therefore resulting in higher levels of very low density lipoprotein 
(VLDL) synthesis and secretion from the liver to the blood stream (20, 21). Alternatively, triose 
phosphates generated from fructose can be oxidized by the hepatocyte, converted to lactate or 
enter the gluconeogenesis (13).  
In addition, high levels of VLDL result in higher concentrations of atherogenic small dense low 
density lipoprotein (sdLDL) due to more extensive lipid remodelling (11, 15, 22). On the other 
hand, fructose decreases lipid degradation via suppression of beta-oxidation (23). After high 
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fructose diets, peroxisome proliferator activated receptor α (PPARα) dependent lipid oxidation 
genes were downregulated and PPARα were reduced in their activity (23). These changes were 
not observed after high glucose consumption (24). Additionally, hepatic de novo lipogenesis 
slows down beta-oxidation by producing malonyl coencyme A (malonyl-CoA), which inhibits 
carnitine palmitoyl transferase I (CPT I) and therefore reduces the entry of fatty acids into the 
mitochondria (22). In short, fructose induces lipid synthesis and therefore causes not only high-
er levels of VLDL synthesis and secretion, but also enhances conversion from VLDL to athero-
genic sdLDL (11, 15, 20, 21, 22).  
 
3.2. Rationale for current study 
Previous studies already investigated effects of fructose on lipid metabolism, but mostly in very 
high doses of pure fructose have been utilized, providing up to 25 - 60% of total daily energy, 
which does not necessarily reflect the amount of fructose currently encountered in the human 
diet (22). There have also been several studies on obese subjects, but the effect of fructose on 
normal weight, healthy subjects remains less clear (15, 25). Besides, it is important to note, that 
fructose is mostly coingested with glucose via sucrose or industrial blends in form of corn syrup 
(22). Therefore, it is necessary not only to examine the effects of fructose on lipid metabolism, 
but also to separate them from the effects of glucose. The consequences of SSB consumption 
in different doses of fructose, glucose or sucrose on lipid metabolism of healthy young male 
subjects was already examined by Aeberli et al. (26), showing the negative impact of SSBs in 
healthy young men on lipid metabolism. This study had two major limitations: Firstly, the inter-
ventions with SSBs only lasted 3 weeks and this may not have been long enough to detect sig-
nificant effects and secondly, there was the possibility of carryover effects between the different 
interventions having a washout period of only ≥4 weeks (26).  
The aim of the current study was to investigate the relations between dietary intake of fructose, 
glucose or sucrose (in amounts comparable to the ones in commercially sweetened beverages) 
and LDL size alternations. The major limitations of the Aeberli et al. study (26) (as just de-
scribed) were corrected in the present study by extending the period of intervention to 7 weeks 
and by appointing to each intervention a different subject in order to avoid a carryover effect. 
Based on literature, the main hypotheses were:  
 Consumption of SSBs causes a reduction in LDL particle size;  
 Fructose-sweetened beverages reduce LDL particle size more than glucose-sweetened 
beverages.  
In conclusion, the objective of the current study was to investigate the effect of moderate SSB 
consumption on LDL particle size alternations in healthy young men.  
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4. Material and Methods 
4.1. Study design 
In this randomized, double blind (relating to SSB intervention), monocentric, controlled nutrition-
al study 96 subjects were included. The investigation of LDL particle size was a secondary out-
come of a larger project investigating changes in fatty acid synthesis due to SSB consumption 
as primary outcome. The subjects were equally divided into 4 groups of 24 subjects each. Each 
of the 4 groups obtained in parallel a different intervention after a baseline examination. There-
fore a randomization procedure was used to avoid a bias. Randomization lists were prepared by 
the hospital pharmacy (Kantonsapotheke Zürich). In general, the different interventions lasted 7 
weeks and subjects were examined in visits at the University Hospital Zurich after week 5, week 
6 and week 7. All subjects were examined in a time interval of April 2013 to December 2015. 
 
During 3 out of 4 interventions, the subjects were supplied with SSBs containing either 80g fruc-
tose per day, 80g glucose per day or 80 g sucrose per day. Subjects were instructed to drink 3 
times a bottle per day, each contained 200ml of water mixed with 26.6g of fructose, glucose or 
sucrose. All bottles were produced by Molkerei Biedermann AG in Bischofszell/TG, Switzerland. 
Subjects of the 4th intervention, serving as control group, abstained completely from SSBs. The 
different interventions were randomly assigned to the subjects. Both the study team and sub-
jects were blinded concerning the intervention with SSBs.  
 
4.2. Subjects 
96 healthy, non-smoking male volunteers (age between 18 and 30 years, body mass index 
(BMI) between 19 and 24 kg/m2) of European ancestry were included in the study. The subjects 
were recruited in student facilities using posters and newspaper advertisements approved by 
the local ethics committee. Only male members were included, since there is evidence of a dif-
ferent metabolic effect of fructose on male and female subjects (27). The following criteria led to 
an exclusion of the subjects:  
 Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold in-
creased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, 
manifested atherosclerosis, or any other disease precluding participation in the study.  
 Diabetes 
 Known alcohol, substance or drug abuse, concomitant medication  
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 More than three hours of physical exercise per week  
 Consumption of more than 1 times 3 dl SSB daily  
 Subjects likely to fail to comply with the study protocol  
 Subjects who participate to another clinical study or have participated to a clinical study 
in the past 6 months  
 Subjects who have donated blood or blood components in the past 6 months  
 Subjects who do not give informed consent 
 
4.3. Study visits 
The study consisted of a screening visit followed by 4 examination visits. In the screening visit, 
all subjects were thoroughly informed about the study and received a proband’s information 
sheet. After obtaining the written informed consent, anamnestic data about the medical history, 
medication and systemic diseases were collected. Then, morphometric measurements (body 
weight, height, BMI) were done and blood samples were taken in order to measure haemoglo-
bin, haematocrit, fasting glucose, plasma lipids liver and renal function (aspartate aminotrans-
ferase (ASAT), alanine aminotransferase (ALAT), creatine kinase (CK), creatinine) and to 
screen for HIV antibodies. All subjects meeting the inclusion criteria without violating the exclu-
sion criteria were included in the study. In general, subjects were informed not to drink SSBs 4 
weeks before the baseline visit. They were instructed to record each time all food and drinks 
consumed 3 days prior to a next visit. In addition, they were told not to eat anything for at least 
12 hours, not to drink alcohol or coffein containing drinks, not to smoke and not to do excessive 
sports during 24 hours prior to the next visit. The evening before a visit, they should abstain 
from fatty meals. 
The examination consisted in total of 4 visits (a baseline visit and a visit after 5, 6 and 7 weeks 
of intervention) at the University Hospital Zurich. In every visit, subjects were provided with 
SSBs and were instructed to drink 3 times a day at every meal one SSB containing 200ml each 
until the next visit (except for the last visit after 7 weeks). Furthermore, the overnight fasting 
blood samples for LDL analysis were drawn in a sitting position at 700 to 800 am in all visits. In 
addition to blood samples, other parameters not relevant to the study described here were 
measured. Subjects were questioned about their sense of wellbeing and about adverse events. 
Also they had to submit their record of eating habits, their empty bottles of SSBs and not con-
sumed bottles of SSBs (except the baseline visit). For the calculation of LDL particle size and 
fractions after the intervention, mean values of the 3 visits after 5, 6 and 7 weeks of intervention 
were generated in order to obtain robust results.  
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4.4. Laboratory analysis 
Laboratory analysis was done in the endocrinology laboratory at the University Hospital Zurich. 
Ethylene diamine tetraacetic acid (EDTA) tubes were used for the overnight fasting blood sam-
ples and were centrifuged within 30 min. Plasma for LDL size analysis was frozen and stored at 
-80°C. Nondenaturating polyacrylamide gradient gel electrophoresis was performed in 2-16% 
polyacralamide gradient gels at 10-14°C. As described in (28, 29, 30), gel electrophoresis was 
performed for 24h at 125 V in tris borate buffer (pH 8.3). In a solution of red O in 60% ethanol at 
55°C gels were fixed and stained for lipids. Gels were photographed with a Canon G3 digital 
camera. The pictures were analysed using the LDL particle analyser program (University Hospi-
tal Zurich) as follows: For each absorbance peak, migration distance was determined and the 
corresponding molecular diameter calculated. The calibration curve was generated from the 
migration distance of standardised substances of known diameter, namely apoferritin and thy-
roglobulin (HMWStd, Pharmacia, Piscataway, NJ) and carboxylated latex beads (Duke scien-
tific, Palo Alto, CA) with a molecular diameter of 122 Å, 170 Å and 380 Å. There were also lipo-
protein calibrator of previously determined particle size used. As previously described in (29), 
LDL subclass distribution in relation to total LDL was calculated.  
 
4.5. Statistical analysis 
Data are described as mean ± standard deviation (SD). Changes of parameter within groups 
were analysed with the Wilcoxon test. Changes between groups were analysed with the Mann-
Whitney or Kruskal-Wallis test. In addition to particle analysis of subgroups, there was an analy-
sis of the interventions as a whole. P-values < 0.05 were considered being significant. 
 
4.6. Ethics 
The study protocol was approved by the ethics committee of the Kanton Zurich (Kantonale 
Ethikkomission Zürich, KEK-ZH Nr. 2012-0160). All subjects were thoroughly informed about 
the study and received a proband’s information sheet. Subjects signed an informed consent 




5.1. Baseline characteristics 
Out of 96 subjects initial assigned, a total of 94 subjects completed the study. 2 Subjects did not 
finish the study. Important characteristics of the subjects are summarized in Table 1. There 
were significant differences among the intervention groups in age (p = 0.012), height (p = 0.039) 
and BMI (p = 0.006) despite randomisation.  
 
 Intervention p 
Control Fructose Glucose Sucrose 
Number 24 24 23 23 - 
Age, (y) 22.5 ± 2.60 23.46 ± 2.34 21.57 ± 2.11 23.26 ± 2.22 0.012 
Weight, (kg) 70.80 ± 7.49 69.98 ± 7.94 71.47 ± 6.79 75.85 ± 7.34 0.337 
Height, (m) 1.82 ± 0.06 1.79 ± 0.06 1.80 ± 0.05 1.82 ± 0.08 0.039 
BMI, (kg/m2) 21.39 ± 1.57 21.76 ± 1.48 21.95 ± 1.58 22.9 ± 1.09 0.006 
Tab 1: Comparison of subject’s characteristics at the screening visit (before the beginning of the trial) for the differ-
ent interventions fructose (Fructose: 80g fructose/d), glucose (Glucose: 80g glucose/d), sucrose (Sucrose: 80g su-
crose/d) and control (Control: abstaining from SSBs). Data are described as mean ± SD. P-values <0.05 were con-































5.2. Effects of SSBs containing fructose, glucose or sucrose on LDL particle dis-
tribution 
Comparing LDL particle peak size after the four interventions, there was no significant differ-
ence between the 4 groups (Figure 1). The amount of large (subclass I) particle LDL decreased 
significantly after the sucrose containing intervention compared with baseline (p = 0.039). De-
spite no significant increase in small LDL particle amount for none of the interventions, there 
was a tendency of LDL subclass III to increase after the fructose containing intervention (p = 
0.06) (Figure 2). When, however, the effects of the different interventions were compared at a 




Fig 1: LDL peak diameter after consumption of fructose 
(Fructose: 80g fructose/d), or glucose (Glucose: 80g glu-
cose/d), or sucrose (Sucrose: 80g sucrose/d) or control 
(Control: abstaining from SSBs). Baseline stands for the 
beginning of the trial (week 0) and Visit represents the 
mean of the three examination days (week 5, 6 and 7).  
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Fig 2: LDL subclasses according to mean percentage of LDL distribution after consumption of fructose (Fructose: 
80g fructose/d), or glucose (Glucose: 80g glucose/d), or sucrose (Sucrose: 80g sucrose/d) or control (Control: ab-
staining from SSBs). LDL subgroup I represents the largest particles (diameter: 27.2-28.5nm), LDL subgroup II the 
second largest particles (diameter: 25.6-27.2nm), LDL subgroup III the third largest particles (diameter: 24.2-25.6nm), 
LDL subgroup IV the smallest particles (diameter: 22.0-24.2nm), LDL subgroup Large the LDL subgroup I and II 
together and LDL subgroup Small the LDL subgroup III and IV together. Baseline stands for the beginning of the trial 
(week 0) and Visit represents the three examination days together (mean after week 5, 6 and 7). * significantly differ-
ent from baseline (p < 0.05).  
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5.3. Effects of the SSB intervention in general on LDL particle distribution 
When LDL particle peak size was compared between the two interventions (control group ver-
sus a combined group of all SSB interventions), there was no significant difference between 
them (Figure 3). The amount of large (subclass I) LDL particles decreased after the SSB inter-
vention significantly (p = 0.022), as well as the amount of large LDL particles in general (p = 
0.044) compared with baseline. There was a significant increase in the amount of small (sub-
class III) LDL particles (p = 0.04) and small LDL particles in general (p = 0.044) compared with 
baseline (Figure 4). When, however, the effects of the SSB intervention and the control group 
were compared at a given time point, there was not found any significant difference. 
 
 
Fig 3: LDL peak diameter after consumption of sugar-
sweetened beverages (Sugar-sweetened beverage: 80g 
fructose/d or 80g glucose/d or 80g sucrose/d) or control 
(Control: abstaining from SSBs). Baseline stands for the 
beginning of the trial (week 0) and Visit represents the 
mean of the three examination days (after week 5, 6 and 













Fig 4: LDL subclasses according to mean percentage of LDL distribution after consumption of sugar-sweetened 
beverages (Sugar-sweetened beverage: 80g fructose/d or 80g glucose/d or 80g sucrose/d) or control (Control: ab-
staining from SSBs). LDL subgroup I represents the largest particles (diameter: 27.2-28.5nm), LDL subgroup II the 
second largest particles (diameter: 25.6-27.2nm), LDL subgroup III the second smallest particles (diameter: 24.2-
25.6nm), LDL subgroup IV the smallest particles (diameter: 22.0-24.2nm), LDL subgroup Large the LDL subgroup I 
and II together and LDL subgroup Small the LDL subgroup III and IV together. Baseline stands for the beginning of 
the trial (week 0) and Visit represents the mean of the three examination days (week 5, 6 and 7). * significantly differ-




In the present study, the amount of small LDL particles increased and the amount of large LDL 
particles decreased after the SSB interventions. Comparing the effects of SSBs sweetened ei-
ther with 80g fructose, 80g glucose or 80g sucrose, there was only found a significant decrease 
in the large, buoyant LDL particles I after the intervention containing sucrose compared with 
baseline. However, despite having no significant increase in the amount of small LDL particles 
for none of the interventions, there was a tendency of the small LDL subclass III to increase 
after the fructose containing intervention. If we summon all SSB interventions and look at it as 
an SSB intervention in general, there was found a significant decrease in the amount of large, 
buoyant LDL particles I and generally in the amount of large LDL particles. Moreover, there was 
a significant increase in the amount of particles in LDL subclass III as well as in small LDL parti-
cles after the SSB intervention in general. Of interest, the baseline characteristics of the inter-
vention groups differed significantly in age, height and BMI at the beginning of the trial despite 
randomization. 
 
6.2. Comparison to other publications 
The findings of this study, namely SSBs decreasing LDL particle size in particular after sucrose 
and fructose-sweetened beverages, but less by glucose-sweetened beverages, are in concord-
ance with the findings of other studies. Aeberli et al. (26). providing healthy young male subjects 
with the same amount of sugars in form of SSBs daily, found the large, buoyant LDL subclass I 
to be significantly decreased compared with baseline after consuming fructose and sucrose-
sweetened beverages. Moreover, they found fructose and sucrose-sweetened beverages to 
decrease the large, buoyant LDL subclass I significantly more than glucose-sweetened bever-
ages. The reason why there was no significant effect of fructose decreasing LDL particle size 
and no significant difference in LDL particle size after the different SSB interventions in the pre-
sent study may be due to an under-powering of the study in the first place. The study was origi-
nally powered for the primary outcome, not for LDL particle size as secondary outcome. Again, 
this may have prevented the discovery of significant differences between the interventions.  
Meanwhile, a study by Stanhope et al. (15) found an increase in LDL and sdLDL both after con-
sumption of fructose-sweetened beverages, but no increase after glucose-sweetened beverag-
es. However, this study was carried out on overweight subjects and the amounts of sugars be-
ing used was higher (25% of daily energy). A dietary analysis by Aeberli et al. (2) of overweight 
school children showed that fructose intake was inversely associated with LDL particle size. 
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Besides adiposity, total fructose intake was found to be the only dietary factor being a significant 
predictor of LDL size. This study, however, was carried out on 6 – 14 year old overweight and 
normal weight children. 
 
6.3. Strengths und limitations of the study 
Being carried out in a randomized, controlled, double-blind manner regarding the SSB interven-
tion, is the main strength of the study. Furthermore, using amounts of sugar reflecting real-life 
intake (80g per day) in form of SSBs counts also to the main strengths of the study. In contrast, 
most previous studies used very high doses of sugars providing up to 25 - 60% of total daily 
energy (22). On the other hand, the sugar composition itself did not reflect the composition of 
sugar being used to sweeten beverages nowadays, for there was only used pure fructose, glu-
cose or sucrose. The study of Aeberli et al. (26) shows the same strengths as just described.  
A main limitation is the under powering of the study for it was originally powered for the primary 
outcome, not for LDL particle size as secondary outcome. This may have prevented the current 
study to find more significant outcomes. Even though there was used a randomization proce-
dure to appoint subjects to the different intervention groups, another limitation represents the 
unequal distribution of baseline characteristics at the beginning of the trial. Theoretically, this 
may have biased the results, however this is unlikely due to the small differences.  
 
6.4. Unanswered questions 
Although this study showed adverse effects of moderate SSB consumption on LDL metabolism 
over a period of 7 weeks, long term impact on LDL metabolism has not been investigated. Fur-
ther studies are needed to show these effects. Also, more research on the relationship between 
LDL size and the occurrence of atherosclerosis, CVD risk and the metabolic syndrome needs to 
be performed. Even though there have already been association studies investigating this (7, 8), 
none of them appeared to be an intervention study showing the direct impact of SSB consump-
tion on morbidity and mortality. A study like this, however, would not be ethically justifiable, thus 





This study shows that even a moderate consumption of SSBs leads to adverse effects on LDL 
metabolism. Further, sucrose and fructose-sweetened beverages seem to be more detrimental 
than glucose-sweetened beverages. The diverse effects on LDL metabolism of the different 
sugars are most probably due to the metabolism of fructose, which in contrast to the metabo-
lism of glucose, does not stand under the regulatory control of insulin and therefore induces lipid 
synthesis unhindered (20, 21). Only over a short period of 7 weeks, moderate consumption of 
SSB may worsen LDL parameters in, healthy young, not predisposed men. As moderate SSB 
consumption leads to an impaired LDL profile, it appears to be a risk factor for metabolic disor-
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